CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
NCT ID: NCT04681131
Last Updated: 2025-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
85 participants
INTERVENTIONAL
2021-03-17
2025-07-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT02151149
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
NCT02250326
A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
NCT00558922
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
NCT01138163
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
NCT02392507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CAB-AXL-ADC (BA3011)
CAB-AXL-ADC (BA3011) alone
CAB-AXL-ADC
Conditionally active biologic anti-AXL antibody drug conjugate
CAB-AXL-ADC (BA3011)+PD-1 inhibitor
CAB-AXL-ADC (BA3011) with PD-1 inhibitor
CAB-AXL-ADC
Conditionally active biologic anti-AXL antibody drug conjugate
PD-1 inhibitor
PD-1 inhibitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAB-AXL-ADC
Conditionally active biologic anti-AXL antibody drug conjugate
PD-1 inhibitor
PD-1 inhibitor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Adequate renal function
* Adequate liver function
* Adequate hematological function
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Life expectancy of at least three months.
Exclusion Criteria
* Patients must not have known non-controlled CNS metastasis.
* Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
* Patients must not have had major surgery within 4 weeks before first BA3011
* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
* Patients must not be women who are pregnant or breast feeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioAtla, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope - Duarte
Duarte, California, United States
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
Irvine, California, United States
California Research Institute
Los Angeles, California, United States
USC Norris
Los Angeles, California, United States
Cedars-Sinai
Los Angeles, California, United States
University of California, San Diego (UCSD) - Moores Cancer Center
San Diego, California, United States
American Institute of Research
Whittier, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Florida Cancer Specialists & Research Institute
Fleming Island, Florida, United States
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, United States
Florida Cancer Specialist
St. Petersburg, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Florida Cancer Specialists
West Palm Beach, Florida, United States
Augusta University - Georgia Cancer Center
Augusta, Georgia, United States
Baptist Health Systems
Lexington, Kentucky, United States
University of Kentucky
Lexington, Kentucky, United States
Norton Cancer Institute, Brownsboro Hospital Campus
Louisville, Kentucky, United States
Hematology/Oncology Clinic
Baton Rouge, Louisiana, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center
Detroit, Michigan, United States
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
OptumCare Cancer Care
Las Vegas, Nevada, United States
Roswell Park
Buffalo, New York, United States
NYU Langone Health
New York, New York, United States
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina, United States
Gabrail Cancer Research Center
Canton, Ohio, United States
The Lindner Research Center at the Christ Hospital
Cincinnati, Ohio, United States
UPMC Cancer Center
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina- Hollings Cancer Center
Charleston, South Carolina, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
MD Anderson
Houston, Texas, United States
Henry Dunant Hospital Center
Athens, , Greece
Metropolitan Hospital Perseus Healthcare Group SA
Piraeus, , Greece
Bioclinic Thessaloniki
Thessaloniki, , Greece
European Interbalkan Medical Center
Thessaloniki, , Greece
ICON Cancer Centre
Hong Kong, , Hong Kong
Queen Mary Hospital
Hong Kong, , Hong Kong
Hong Kong United Oncology Centre
Kowloon, , Hong Kong
"IRCCS Osp. Policlinico San Martino Pad Ex microbiologia, stanza 9, 1 piano."
Genoa, Liguria, Italy
Hospital San Giuseppe Moscati
Avellino, , Italy
European Institute of Oncology (IEO), IRCCS
Milan, , Italy
Santa Maria delle Croci Hospital of Ravenna
Ravenna, , Italy
Integrated University Hospital of Verona
Verona, , Italy
MED-Polonia, Sp. z o.o. (LLC)
Poznan, Greater Poland Voivodeship, Poland
Institute of Genetics and Immunology GENIM
Lublin, Lublin Voivodeship, Poland
Maria Sklodowska-Curie - National Research Institute of Oncology
Warsaw, Masovian Voivodeship, Poland
Polish Mother's Memorial Hospital-Research Institute
Lodz, Łódź Voivodeship, Poland
Specialistic Oncologic Hospital NU-MED
Tomaszów Mazowiecki, Łódź Voivodeship, Poland
Hospital Universitario Virgen de Valme
Seville, Andalusia, Spain
Hospital del Mar
Barcelona, Catalonia, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain
Catalan Institute of Oncology, Hospital Duran i Reynals
Barcelona, Catalonia, Spain
University Hospital 12 de Octubre
Madrid, Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Kaoshiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BA3011-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.